Tolterodine Tartrate Tablet, Film Coated
Product Images NDC 31722-805
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tolterodine Tartrate (NDC 31722-805). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Structure (Structure)
Table-1 (Table 1)
This appears to be a table displaying various pharmacokinetic parameters of Tolterodine and its metabolite 5-Hydroxymethyl Metabolite for different phenotypes (EM and PM) and administration modes (single-dose and multiple-dose). The parameters include tmax, Cmax, Cavg, ti2, CL/F, and Crax. However, without additional context or units for the measurements, it is difficult to provide a more detailed description.*
Table-2 (Table 2)
This appears to be a table with information about the effects of drugs on QTc intervals, which is a measure of heart function. The drugs listed are Toltsrodineng and Moxifocacin, with various dosages and frequencies listed. The table includes measurements taken both manually and with a machine and provides the corresponding QTcF and QTcP values in milliseconds. However, the numbers are unclear and difficult to interpret due to the format of the text, which seems to have been obtained by .*
Table-3 (Table 3)
The text provides results from a study evaluating the effects of tolterodine tartrate tablets compared to placebo on urinary incontinence, micturitions per 24 hours, and volume voided per micturition. The study included 514 participants in the tolterodine group and 508 participants in the placebo group. Results showed a statistically significant difference between the two groups in terms of the number of incontinence episodes per week and volume voided per micturition. However, there was not a statistically significant difference between the two groups in terms of the number of micturitions per 24 hours.*
Table-4 (Table 4)
The table shows the 95% Confidence Intervals for the difference between Tolterodine Tartrate Tablets (2 mg bid) and Placebo for the Mean Change at Week 12 from Baseline in Studies 008, 009, and 010. It provides information on the number of patients, mean baseline, mean changes from baseline, and the difference between Tolterodine and Placebo for different parameters such as the number of incontinence episodes per 24 hours, number of micturitions per 24 hours, and volume voided per micturition (mL).*
Toltcontlabel1mg60s (Toltcontlabel1mg60s)
Camber Pharmaceuticals manufactured Tolterodine Tartrate Tablets labelled NDC 31722-805-60 for prescribed use only which contains 1mg Tolterodine tartrate USP. The usual adult dosage is available in the package insert. Store in tight containers at 20° to 25°C (68° to 77°F). Contact 1-866-495-1995 in the USA for more information. Manufactured by Annora Pharma Pvt Ltd. in Telangana, India. Mfg. Lic. No.: 24/MD/TS/2016/F/G. Size is approximately 40 x 30 mm with an unvarnished area. If you have any medical queries, information is available at http://camberpharma.com/medication-quides.*
Toltcontlabel2mg60s (Toltcontlabel2mg60s)
Camber's Tolterodine Tartrate Tablets contain 2mg of Tolterodine tartrate USP per tablet that is used for adults. It is recommended to refer to the package insert for complete prescribing information. This medication should be stored at 20-25°C (68-77°F) and dispensed in tight containers. Patients can contact Camber Pharmaceuticals to obtain more information or to report adverse reactions. Lastly, these tablets were manufactured by Annora Pharma Pvt. Ltd in Telangana, India.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.